Semnur Pharmaceuticals, Inc.

Semnur Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company that focuses on developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its lead product candidate is SP-102, a novel viscous gel formulation of corticosteroid designed to treat lumbosacral radicular pain, commonly known as sciatica. SP-102 is currently in its second Phase 3 study. The company operates as a subsidiary of Scilex Holding Company and is headquartered in Palo Alto, California.

Semnur Pharmaceuticals, Inc. is listed on the OTC Markets under the OTCPK exchange, with the ticker symbol SMNR. The company trades in US Dollars (USD), reflecting its primary operations in the United States.

Semnur Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. As a biopharmaceutical company, it focuses on the research, development, and potential commercialization of innovative therapies, particularly in the area of non-opioid pain management.

Semnur Pharmaceuticals, Inc. is headquartered in Palo Alto, California, United States. The company was founded in 2013 and operates as a subsidiary of Scilex Holding Company. Its primary focus is on developing non-opioid treatments for pain, with its lead candidate SP-102 targeting sciatica.